Figure 2 | Scientific Reports

Figure 2

From: Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response

Figure 2

GB265/266/266T MsAbs mediate interactions between T cells and cancer cells. (a) Jurkat LAG-3 or TIGIT cells were labeled with ViaFluor 488, and incubated with RKO cells (PD-L1+CD155+) labeled with ViaFluor 405, in the presence of indicated antibodies (0.2 nM). Cell conjugates (events double-positive for the two fluorescent dyes. Boxed in red) were measured by flow cytometry. (b, c) Diagram showing the mechanism of GB265/266/266T-mediated tumor cell/T cell bridging. (d, e), Dose-dependent bridging of cancer cells with T cells by GB265/266/266T. Assays were performed in duplicates, and data are presented as mean ± SD.

Back to article page